---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-012433"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2023-09-29T23:59:59+00:00"
generated_at: "2026-06-10T07:13:57.578152+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics gets Nasdaq extension to March 25, 2024 for $1 bid price rule

## Summary
- Nasdaq granted extension through March 25, 2024 to regain compliance with $1.00 minimum bid price (Rule 5550(a)(2)).
- Original compliance period ended Sept. 25, 2023; extension provides six additional months.
- If bid price closes at $1.00+ for ten consecutive days, Nasdaq will confirm compliance.
- If not compliant by March 25, 2024, Nasdaq will issue delisting notice; company may appeal.
- Company evaluating options including reverse stock split; no assurance of regaining compliance.

## SEC filing metadata
- accession: 0001654954-23-012433
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2023-09-29T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495423012433/0001654954-23-012433-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495423012433/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-012433
- JSON: https://secwatch.observer/filing/0001654954-23-012433.json
- Plain text: https://secwatch.observer/filing/0001654954-23-012433.txt

## Key facts
- Listing & Compliance Notices
  TENAX THERAPEUTICS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: September 28, 2023, Tenax Therapeutics, Inc. (the “Company”) received formal notice that the Nasdaq Stock Market LLC (“Nasdaq”) granted the Company’s request for an extension through March 25, 2024 (the “Extension Notice”) to evidence compliance with the $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). If at any time before March 25, 2024, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, Nasdaq will provide the Company w
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000165495423012433/0001654954-23-012433-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.